Exploring Therapeutic Strategies in Myelodysplastic Syndromes

Oncologists who specialize in the treatment of hematologic malignancies participated in a virtual workshop to discuss the emerging treatment landscape in myelodysplastic syndromes.

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Jamile M. Shammo, MD, discusses the current treatment landscape of high-risk MDS recent data with the investigational small molecule inhibitor of the NEDD8-activating enzyme pevonedistat, and ongoing research efforts in the space.

Daniel J. DeAngelo, MD, PhD, discusses the utility of the investigational agent pevonedistat in myelodysplastic syndrome.

Rami Komrokji, MD, discusses the current treatment landscape in myelodysplastic syndrome.